Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis marks a pivotal moment for ADC therapies in oncology, reflecting the FDA’s growing confidence in ...

ABUJA – In a bold move to reposition itself as a credible opposition platform, the African Democratic Congress (ADC) has approved the appointment of several prominent political figures, including ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

Lieutenant Commander Yashasvi Solanki, 27, has made history as the first female Aide-de-Camp (ADC) to the President of India, Droupadi Murmu. She officially took over the role on May 9, 2025, after a ...

The antibody-drug conjugate (ADC) field is advancing at an unprecedented pace, with groundbreaking innovations and soaring investment. A 33% rise in new drugs, a surge in clinical trials, and ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio, Inc. and Charles River Laboratories, Inc. have announced a strategic alliance to offer complementary services to clients including early development and ...

Despite some positive trials with new drugs (including immunotherapy) for recurrent cervical cancer, the prognosis for this disease remains poor and additional treatment options are needed. Tisotumab ...

In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody-drug conjugate (ADC) patritumab deruxtecan. The drug, also known as HER3-DXd, was ...